OR2L13 and triple-A syndrome: Global olfr168–/– mice were used as proof of principle that OR2L13 protects against platelet activation, platelet and aortic MMP activation, and aortic rupture in AAA, but an intrinsic limitation is a lack of availability of mice with platelet-specific olfr168 deletion.